KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Inventory (2020 - 2025)

Esperion Therapeutics' Inventory history spans 6 years, with the latest figure at $105.1 million for Q4 2025.

  • For Q4 2025, Inventory rose 11.25% year-over-year to $105.1 million; the TTM value through Dec 2025 reached $105.1 million, up 11.25%, while the annual FY2025 figure was $105.1 million, 11.25% up from the prior year.
  • Inventory reached $105.1 million in Q4 2025 per ESPR's latest filing, down from $108.5 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $114.5 million in Q2 2025 to a low of $20.0 million in Q1 2021.
  • Average Inventory over 5 years is $60.2 million, with a median of $48.6 million recorded in 2023.
  • Peak YoY movement for Inventory: skyrocketed 988.0% in 2021, then dropped 13.03% in 2022.
  • A 5-year view of Inventory shows it stood at $34.4 million in 2021, then increased by 2.35% to $35.2 million in 2022, then skyrocketed by 86.42% to $65.6 million in 2023, then skyrocketed by 43.99% to $94.5 million in 2024, then grew by 11.25% to $105.1 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Inventory are $105.1 million (Q4 2025), $108.5 million (Q3 2025), and $114.5 million (Q2 2025).